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Abstract
Accumulating evidence from experimental animal models
suggests that antibodies play a protective role against tuberculo-
sis (TB). However, little is known about the antibodies generated
upon Mycobacterium tuberculosis (MTB) exposure in humans.
Here, we performed a molecular and functional characterization
of the human B-cell response to MTB by generating recombinant
monoclonal antibodies from single isolated B cells of untreated
adult patients with acute pulmonary TB and from MTB-exposed
healthcare workers. The data suggest that the acute plasmablast
response to MTB originates from reactivated memory B cells and
indicates a mucosal origin. Through functional analyses, we iden-
tified MTB inhibitory antibodies against mycobacterial antigens
including virulence factors that play important roles in host cell
infection. The inhibitory activity of anti-MTB antibodies was
directly linked to their isotype. Monoclonal as well as purified
serum IgA antibodies showed MTB blocking activity indepen-
dently of Fc alpha receptor expression, whereas IgG antibodies
promoted the host cell infection. Together, the data provide
molecular insights into the human antibody response to MTB
and may thereby facilitate the design of protective vaccination
strategies.
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Introduction
Tuberculosis (TB) is a major cause of death worldwide. Despite the
extensive research, no effective vaccine against adult pulmonary TB
has been developed (Andersen & Kaufmann, 2014). Therefore, long-
term antibiotic treatment remains the standard of care (Zumla et al,
2013).
Stable Mycobacterium tuberculosis (MTB) infection is established
in the lung after bacterial uptake by macrophages, which generally
fail to eliminate the bacteria and instead serve as major MTB reser-
voir (Guirado et al, 2013). However, mycobacteria can also directly
infect and replicate within epithelial cells, which has been associ-
ated with mycobacterial dissemination from the lung (Pethe et al,
2001; Castro-Garza et al, 2002). Surface-exposed MTB antigens play
a major role in host cell invasion as shown, for example, for
heparin-binding hemagglutinin (HBHA), an adhesion molecule that
interacts with proteoglycans on the surface of epithelial cells,
thereby facilitating MTB entry (Pethe et al, 2001; Locht et al, 2006;
Menozzi et al, 2006). Moreover, lipids and lipoglycans, such as the
abundant lipoarabinomannan (LAM), are major components of the
MTB cell wall and promote the bacterial uptake through the interac-
tion with mannose receptors expressed on the host cell surface
(Schlesinger et al, 1994; Kang et al, 2005; Torrelles et al, 2008).
It is long known that T cells play a major role in TB immunity
and are the target of current vaccination strategies (Cooper, 2009;
Andersen & Kaufmann, 2014). However, more recent evidence
points toward a role of B cells in modulating immune responses to
MTB infection, for example, as antigen-presenting cells or through
the production of cytokines and antibodies (Glatman-Freedman &
Casadevall, 1998; Teitelbaum et al, 1998; Bosio et al, 2000;
Chambers et al, 2004; Roy et al, 2005; Maglione et al, 2007, 2008;
Achkar et al, 2015). Antibodies can exert their functions in two
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ways: by the direct blocking of host cell invasion and neutralization
of bacterial products, or indirectly through Fc-mediated complement
and cell activation mechanisms through Fc receptors (Ravetch &
Clynes, 1998). Steady-state mucosal immune responses are charac-
terized by the production of IgA, whereas inflammatory conditions—
including acute pulmonary TB—are associated with class switching
to IgG (Brandtzaeg et al, 1997; Demkow et al, 2007).
Recent studies revealed that monoclonal antibodies against vari-
ous mycobacterial surface antigens including LAM and HBHA can
mediate protection in mouse models (Teitelbaum et al, 1998; Pethe
et al, 2001; Chambers et al, 2004; Hamasur et al, 2004; Lopez et al,
2009). However, whether MTB-neutralizing antibodies against these
structures also develop upon natural exposure in humans and
induce the formation of B-cell memory remains to be determined.
To address these questions, we analyzed the antibody repertoire of
plasmablasts, a population of antibody-secreting B cells that circu-
late transiently in the blood upon acute infection and reflect the
ongoing humoral immune response to pathogens, and the memory
B-cell response to HBHA (Wrammert et al, 2008; Li et al, 2012). We
demonstrate that MTB-exposed healthcare workers (HCW) and
patients with active pulmonary TB generate B-cell antibody
responses against mycobacterial surface antigens including LAM
and HBHA, which mediate protection against the host cell invasion.
Surprisingly, our data demonstrate that the inhibitory activity of
anti-MTB antibodies depends directly on their isotype. IgA, but not
IgG, antibodies specific for different MTB surface antigens can block
MTB uptake by lung epithelial cells independently of the expression
of IgA Fc receptors.
Results
Human anti-MTB plasmablast and memory B-cell
antibody response
To characterize the antibody response to MTB, we initially screened
peripheral blood samples from a cohort of 17 untreated and 8 drug-
treated patients with active pulmonary TB for the presence of circu-
lating plasmablasts and for serum antibody reactivity to MTB anti-
gens (Fig 1). Healthy donors (HD) without contact with TB patients
served as controls. About 50% of patients mounted specific IgG and
IgA serum responses against MTB with higher antibody levels
against cell membrane antigens compared with secreted culture fil-
trate proteins (Fig 1A and B). Circulating CD19+CD27++CD38+
plasmablasts were present in about 38% of all patients (Fig 1C). The
cells expressed low levels of CD19 and were positive for the surface
markers CD86, CD84, and CD24 indicative of their recent activation
status (Fig 1D). The frequency of plasmablasts was highest during
early acute TB and waned upon drug treatment, whereas serum IgG
levels increased over six months of antibiotic combination therapy
(Fig 1E). Several untreated patients with prominent serum antibody
responses lacked the detectable plasmablast levels in the circulation,
suggesting that these donors had been infected for prolonged times
so that their circulating plasmablast response had waned (Fig 1F).
Next, we selected three patients with circulating plasmablasts
and strong anti-MTB serum Ig responses for the molecular charac-
terization of their plasmablast antibodies (TB7, TB24, TB33; Fig 2A;
Appendix Table S1). From these donors, the IGH and corresponding
IGK or IGL light chain transcripts of over 230 single isolated plas-
mablasts were amplified and sequenced (GenBank accession
number KX947385–KX949063). To exclude any influence of the
antibiotic drug treatment on our analyses, all samples were taken
before the onset of therapy (Appendix Table S1). Consistently, the
majority of TB plasmablasts in all donors expressed somatically
mutated antibodies encoded by diverse Ig genes (Fig 2B;
Appendix Table S2). MTB expresses a large number of diverse anti-
gens. We therefore expected a high degree of polyclonality in the
plasmablast response. Indeed, only a few cells from individual
donors expressed Ig genes with identical heavy and light chain rear-
rangements as well as shared somatic mutations and thus were
clonally related (GenBank accession number KX947385–KX949063).
The relative bias toward IgA and near-complete absence of IgM
expression compared with circulating memory B cells from the same
donors indicated a mucosal origin (Fig 2C).
Plasmablasts can develop from naı¨ve B cells or mutated
memory B cells. The relatively high frequency of somatic muta-
tions in plasmablasts at the levels comparable to circulating
memory B cells under steady-state conditions suggested that the
plasmablast response developed from reactivated memory B cells
rather than from nonmutated naı¨ve B cells that had been newly
activated during active disease onset (Fig 2B; Tiller et al, 2007).
To determine whether circulating anti-MTB memory B cells were
detectable in the absence of active disease, we screened a cohort
of healthy MTB-exposed HCW for the presence of circulating
▸Figure 1. Anti-MTB serum antibody response in the peripheral blood of TB patients.A Serum IgG ELISA reactivity with MTB (H37Rv) whole-cell lysate, purified cell membrane fraction, and secreted culture filtrate proteins (CFP) for TB patients and
healthy donors (HD). ELISA graphs (left; TB: black lines; n = 25; HD: red dotted lines; n = 2) and area under the curve (AUC) values for all tested samples (right; TB:
n = 25; HD: n = 17) are shown. Median is shown.
B AUC values for the IgA serum ELISA response against MTB whole-cell lysate, purified cell membrane fraction, and secreted culture filtrate proteins (CFP) of TB patients
(n = 25) and healthy donors (HD; n = 9). Median is shown.
C Flow cytometric gating strategy and frequency of circulating plasmablasts (CD19+CD27++CD38+) for one representative TB patient (TB24) and HD (left). Frequency of
circulating CD19+CD27++CD38+ plasmablasts of all CD19+ B cells in the peripheral blood of TB patients (n = 24) and HD (n = 8). Dashed line indicates the threshold
for detectable plasmablast populations (right). Median and SEM are shown.
D Expression of CD19 and activation markers (CD86, CD84, and CD24) in the plasmablasts and memory B cells as measured by flow cytometry.
E Plasmablast response of patient TB7 (top) and IgG serum response against MTB cell lysates of patients TB7, TB19, and TB39 (bottom) and one HD at the indicated
time points before and after the treatment onset.
F Dots indicate AUC values for the anti-MTB cell lysate IgG serum ELISA response (y-axis) versus the frequency of circulating plasmablasts (x-axis) for individual TB
patients. Spearman’s correlation and corresponding P-value are shown.
Data information: All data are representative of two independent experiments. (A and B) P-values were determined using Mann–Whitney test; **P < 0.01;
****P < 0.0001; ns, not significant.
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anti-MTB memory B cells. To identify MTB-reactive memory B cells
among all circulating memory B cells, we focused our analysis on
HBHA as representative MTB antigen and performed flow cytome-
try with fluorescently labeled HBHA to detect HBHA-reactive
memory B cells in these donors compared with TB patients
(Fig 2D and E). Although TB patients showed significantly
reduced overall memory B-cell frequencies compared with HD, we
identified individual TB patients and MTB-exposed HCW with
anti-HBHA memory B-cell responses (Fig 2E and F; Abreu et al,
2014). To determine the somatic mutation levels and the isotype
distribution in these cells, we amplified and sequenced the Ig
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and four TB patients with anti-HBHA serum titers (Fig 2G).
Nearly all antibodies were somatically mutated at the levels
comparable to the published data from unselected memory B cells
of HD and we identified clusters of clonally expanded cells in all
four donors (Fig 2H and I; Tsuiji et al, 2006; Tiller et al, 2007;
Berkowska et al, 2015). IGH gene isotype analyses revealed a
clear dominance of IgA and IgM over IgG anti-HBHA memory
B-cell antibodies. The low frequency of IgG was more pronounced
in HCW than in TB patients, whereas IgA was particularly more
abundant in HCW, suggesting an association of disease onset with
the induction of IgG responses (Fig 2J).
In summary, the data provide evidence that circulating plas-
mablasts in the peripheral blood of patients with active pulmonary
TB develop from a polyclonal set of mutated and reactivated
memory B cells. The high frequency of IgA anti-HBHA memory B
cells in HCW suggests that memory is formed upon primary MTB
exposure presumably from mucosal immune responses. Active TB
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formation of plasmablast responses that are associated with class
switching to IgG.
Plasmablast antibodies frequently target MTB surface antigens
Antibodies targeting surface-exposed bacterial antigens likely play a
functional role in the anti-MTB response. To determine whether the
B-cell response to MTB produces functional antibodies, we cloned
the IGH and corresponding IGK or IGL genes from 113 IgA+ and
IgG+ plasmablasts and produced the recombinant monoclonal anti-
bodies in vitro (Appendix Table S2). All antibodies were initially
produced as IgG1 to allow for the direct comparison of their anti-
gen-binding capacity independently of the original plasmablast
isotype. We then tested the antibodies for binding to MTB cell lysate
or whole bacteria by ELISA (Fig 3A and B). On average, 40% of all
recombinant monoclonal antibodies were MTB reactive in these
assays (Fig 3C). To identify nonspecific binding of antibodies, we
also tested all antibodies for binding to irrelevant and structurally
diverse antigens (dsDNA, insulin, LPS). Cross-reactivity was
detected for about 16% of antibodies, indicating that the majority of
plasmablast antibodies were antigen specific (Appendix Table S2).
A large fraction of anti-MTB antibodies recognized whole MTB
bacteria in the ELISA, suggesting that they may target bacterial
surface antigens (Fig 3B). We therefore tested a selected set of MTB-
reactive and nonreactive antibodies for binding to cell membrane
antigens by ELISA (Fig 3D). Indeed, the majority (57.6%, 15/26) of
anti-MTB but only 1 of 15 nonreactive control antibodies was reac-
tive with purified cell membrane antigens (Appendix Table S2). For
individual antibodies, binding to the mycobacterial surface was con-
firmed by flow cytometry, suggesting that they recognized epitopes
that are accessible to antibodies in vivo (Fig 3E and
Appendix Table S2). Thus, the human plasmablast antibody
response to MTB infection predominantly targets mycobacterial
surface antigens.
LAM is a major component of the mycobacterial cell surface and
a target of protective antibodies (Brown et al, 2003; Hamasur et al,
2004). We therefore interrogated whether LAM served as target
antigen of human anti-MTB plasmablast antibodies (Fig 4A–C;
Appendix Table S2). By Western blot, FACS, and ELISA, we identi-
fied two antibodies that recognize MTB ManLAM. Antibody
TB24PB037 lacked reactivity with PILAM from the nonpathogenic
Mycobacterium smegmatis, demonstrating its high specificity for
MTB compared with the CS-35-positive control antibody (Fig 4D).
HBHA represents another surface antigen and MTB virulence
factor, which is targeted by antibodies (Menozzi et al, 1996; Pethe
et al, 2001; Kohama et al, 2008). Although none of the plasmablast
antibodies recognized HBHA (data not shown), the detection of
HBHA-reactive memory B cells in HCW and TB patients with acute
disease (Fig 2D and F) prompted us to determine whether these
cells expressed HBHA-specific antibodies (Fig 4E–G). Upon Ig gene
cloning and in vitro expression of antibodies from HBHA-reactive
memory B cells, we identified 25 HBHA binders by ELISA or
Western blot. Thirteen antibodies of all isotypes lacked cross-
reactivity and were therefore HBHA specific (Appendix Table S3).
Binding of HBHA-reactive antibodies to the outer surface of
mycobacteria was confirmed by fluorescence microscopy (Fig 4G).
Thus, we conclude that MTB-exposed individuals mount high-
affinity plasmablast and memory antibody responses against MTB
surface antigens such as ManLAM and HBHA relevant for host cell
infection.
Antibody isotype-dependent functional differences in
MTB inhibition
To determine the potential role of both plasmablast and memory
B-cell antibodies in MTB infection, we tested a selected set of 41
MTB-reactive recombinant monoclonal antibodies in an in vitro
infection assay with A549 human lung epithelial cells (Fig 5 and
Appendix Table S4). A549 cells are type II alveolar epithelial cells
that have been shown to play a role in early MTB infection
(Bermudez & Goodman, 1996; Castro-Garza et al, 2002; Sato et al,
2002; Ryndak et al, 2015; Zimmermann et al, 2016). We initially
expressed and tested a set of antibodies that had been cloned from
IgA-positive plasmablasts including the anti-LAM antibody
TB24PB037 (Fig 5A and B). To mimic the original plasmablast and
memory B-cell isotype and subclass, we expressed the antibodies as
◀ Figure 2. Somatic hypermutation level and isotype distribution of single-cell-sorted plasmablasts and antigen-specific memory B cells.A Gating strategy, phenotype, and frequency of circulating plasmablasts (CD19+CD27++CD38+) isolated by flow cytometric cell sorting from three TB patients (TB7, TB24,
and TB33) in comparison with one representative HD. Boxes indicate sort gates. The plasmablast frequency is indicated.
B Absolute number of somatic hypermutations (SHM) in the IGHV, IGKV, and IGLV segments of IgA and IgG plasmablast antibody genes sequenced from TB7, TB24, and
TB33. The absolute number of sequences analyzed is indicated below the graph. Geometric means with SEM are indicated in gray. SHM means of historic data from
sorted CD27+IgA+ or CD27+IgG+ cells from the peripheral blood of HD are indicated in red for comparison (Tiller et al, 2007; Berkowska et al, 2015).
C Isotype distribution of plasmablast and memory B cells from TB7, TB24, and TB33. PB, plasmablasts (CD19+CD27++CD38+); M, memory B cells (CD19+CD27+).
D Gating strategy, phenotype, and frequency of HBHA-reactive memory B cells (CD19+CD27+HBHA+) in the peripheral blood of one representative TB patient (TB29),
healthcare worker (HCW) 2, and HD, respectively.
E Dots indicate the frequency of HBHA-reactive memory B cells out of all CD27+ memory B cells in individual TB patients (n = 23) and HCW (n = 7). Mean and SEM are
indicated. P-value was determined using Wilcoxon–Mann–Whitney test; ****P < 0.0001.
F Dots indicate the frequency of resting memory B cells (CD19+CD27+CD10) out of all B cells in the peripheral blood of individual TB patients compared with HCW.
G Anti-HBHA serum IgG ELISA reactivity for TB patients and HCW (black lines) compared with two representative HDs (red lines). Dashed line indicates the threshold
OD405 nm for positive reactivity. Asterisks indicate the serum responses of donors selected for single sorting of HBHA-reactive memory B cells. Data are representative
of two independent experiments.
H Absolute number of somatic hypermutations (SHM) in the IGHV (IGHA, IGHG, and IGHM), IGKV, or IGLV segments of sorted anti-HBHA memory cells from TB patients
and HCW. Geometric means with SEM are indicated in gray. For comparison, red lines indicate the historic SHM means for randomly sorted CD27+IgA+, CD27+IgG+, or
CD27+IgM+ cells from the peripheral blood of HDs (Tsuiji et al, 2006; Tiller et al, 2007; Berkowska et al, 2015).
I The number and size of clonally expanded B-cell clusters among HBHA-reactive memory B cells from two TB patients (TB35 and TB29) and HCW (HCW1 and HCW2).
Cells in clusters are indicated in gray, and single cells are indicated in white. No B-cell clusters were shared between donors.
J IgA, IgG, and IgM isotype distribution of single-cell-sorted HBHA-reactive memory cells. Mean and SEM are indicated.
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IgA1 or IgA2, respectively (Appendix Table S2; Lorin & Mouquet,
2015). For TB24PB037 and six additional plasmablast antibodies of
unknown antigen specificity, preincubation of the mycobacteria
reduced the intracellular bacterial load by 20–50% compared with
the medium control, whereas 5/12 IgA plasmablast antibodies and
the non-MTB-reactive isotype control showed no effect (Fig 5A
and B). Inhibition was not associated with a specific IgA subclass,
suggesting that the differences in the functional properties of indi-
vidual plasmablast antibodies can be explained by the differences in
the target antigen/epitope specificity or affinity. Antibodies without
effect may target antigens or epitopes irrelevant for infection.
To determine whether IgG plasmablast antibodies showed simi-
lar inhibitory activities for MTB, we tested 26 MTB-reactive IgG anti-
bodies that had been cloned from IgG+ plasmablasts in the same
assay (Fig 5A and B). Surprisingly, none of the IgG antibodies was
able to inhibit infection. Instead, most monoclonal anti-MTB IgG
plasmablast antibodies increased the mycobacterial load (Fig 5B).
The results were confirmed with anti-HBHA memory B-cell IgA and
IgG antibodies (Fig 5C and D). Whereas IgA anti-HBHA monoclonal
antibodies impaired the infection, HBHA-reactive IgG antibodies
promoted the infection or had no effect.
The observation that IgA antibodies inhibited the infection of
epithelial cells whereas IgG antibodies promoted mycobacterial
invasion suggested that the differences in isotype rather than
antigen or epitope specificity were associated with functional
differences in MTB inhibitory activity. We therefore cloned and
directly compared IgG and IgA versions of 10 MTB-reactive antibod-
ies including the anti-LAM antibodies (Fig 5E). Indeed, for all tested
antibodies, IgG increased, while IgA decreased the bacterial load.
Antigen binding was not influenced by antibody isotype as









































































































































































Figure 3. Peripheral plasmablast antibodies from TB patients bind to mycobacterial surface antigens.
A total of 113 recombinant monoclonal plasmablast antibodies were generated and characterized for antimycobacterial reactivity.
A, B Representative ELISA graphs show the reactivity of antibodies from patient TB7 to (A) MTB whole-cell lysate or (B) MTB bacteria (left). Dashed red line indicates the
threshold OD405 nm for positive reactivity. Green line indicates the negative control antibody (mGO53; Wardemann et al, 2003). AUC (area under curve) values
indicate the reactivity to (A) MTB cell lysate or (B) whole MTB bacteria for antibodies from TB7, TB24, and TB33. The total numbers of analyzed antibodies are
indicated (right).
C Pie charts show the frequency of MTB-reactive (gray) vs. nonreactive (white) antibodies as measured by whole-cell lysate and MTB bacteria ELISA for each patient.
MTB-reactive antibodies were positive in both or one of the assays. The total numbers of analyzed antibodies are indicated in the center of the charts.
D ELISA graph shows the reactivity to the MTB cell membrane fraction for MTB-reactive (n = 26) and nonreactive (n = 14) antibodies.
E Reactivity to whole BCG bacteria as determined by flow cytometry for three representative MTB cell lysate-reactive antibodies and one nonreactive antibody
(isotype control, mGO53).
Data information: All data in (A, B, D, E) are representative of at least two independent experiments.
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Figure 4. The surface-exposed virulence factors LAM and HBHA are targets of the human plasmablast and memory B-cell response to MTB.
A Binding of antibodies TB24PB037 and TB33PB123 to LAM purified from MTB as determined by Western blot. The negative isotype control (mGO53) and a commercially
available anti-LAM antibody (positive control) are shown for comparison.
B Anti-BCG specificity of the LAM-reactive antibody TB24PB037 (black) compared with E. coli as determined by ELISA with whole bacteria (left) and flow cytometry
(right).
C Anti-LAM ELISA for TB24PB037 or negative control antibody at the indicated concentrations. The mean  SD of the absorbance was calculated.
D Antibody TB24PB037 binds to MTB-LAM, but not to LAM from M. smegmatis. ELISA performed as described in (C). The mean  SD of the absorbance was calculated.
E Representative HBHA ELISA for antibodies cloned from HBHA-reactive memory B cells of patient TB35 and HCW1. Dashed red line indicates the threshold OD405 nm
for positive reactivity. Green line indicates the negative control antibody (mGO53; Wardemann et al, 2003).
F Reactivity to HBHA was confirmed by Western blot for a selected set of antibodies with HBHA ELISA reactivity.
G Fluorescence microscopy shows BCG and MTB reactivity of representative anti-HBHA antibodies compared with a nonreactive isotype control antibody. Scale bars,
10 lm.
Data information: All data are representative of two independent experiments.
Source data are available online for this figure.
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Figure 5. IgA and IgG isotype-dependent functional differences in the effect of monoclonal antibodies on MTB infection of human lung epithelial cells.
Relative bacterial counts (CFU) compared with the medium control (100%; dashed lines) in human lung epithelial A549 cells 1 h after infection with MTB, preincubated with
recombinant MTB-reactive IgA1, IgA2, or IgG1 antibodies and nonreactive isotype control as indicated.
A Representative results for individual MTB-reactive plasmablast antibodies. Mean and SEM are indicated.
B Direct comparison of all tested MTB-reactive IgA (n = 12) and IgG (n = 26) antibodies.
C Representative results for individual HBHA-reactive memory B-cell antibodies from TB patients and HCW.
D Same as in (B) but with HBHA-reactive antibodies as shown in (C). Direct comparison of all tested HBHA-reactive IgA (n = 6) and IgG (n = 7) antibodies.
E Direct comparison of the indicated MTB-reactive antibodies expressed as IgA and IgG. Mean and SEM are indicated.
Data information: Data are representative of at least two independent experiments with three technical replicates each. (B, D) P-values were determined using
Wilcoxon–Mann–Whitney test, ***P < 0.001; ****P < 0.0001. (E) P-values were determined using nonparametric t-test, *P < 0.1; **P < 0.01, ns: P > 0.5.
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To determine whether the differential expression of Fc receptors
may be underlying the isotype-dependent differences in antibody-
mediated inhibition, we used flow cytometry and PCR to measure
the IgG and IgA Fc receptor expression levels of A549 and primary
human airway epithelial cells (Fig 6A and B). Compared with THP-1
macrophages as a positive control, A549 and primary human airway
epithelial cells did not express the IgA Fc receptor CD89 or conven-
tional IgG Fc receptors, which promote the bacterial uptake through
IgG immune complexes (Fig 6A). However, epithelial cells were
positive for the neonatal Fc receptor, which efficiently binds IgG
and could thereby promote cell infection (Fig 6B; Spiekermann
et al, 2002). Despite the difference in CD89 and FccR expression,
infection of macrophages with anti-LAM (TB24PB037) IgA- or IgG-
coated MTB (Fig 6C) reproduced our findings in the epithelial cells
(Fig 5). Preincubation with IgA reduced the bacterial load, whereas
IgG did not. We conclude that the IgA-mediated blocking effect of
MTB uptake (Figs 5 and 6C) was not IgA Fc receptor mediated and
uptake of IgG-coated bacteria was not influenced by FccR but more
likely by FcRn expression.
To determine whether isotype-associated differences in mycobac-
terial uptake were also observed for serum antibodies, we purified
serum IgA and IgG from TB patients and non-TB-exposed HDs
(Fig 7). Increased uptake of MTB by A549 cells was detected for
purified polyclonal IgG preparations from the serum of individual
TB patients, whereas purified serum IgA reduced the mycobacterial
load similar to the monoclonal plasmablast antibodies (Fig 7A and
B). In summary, our data suggest that isotype plays a critical role in
determining the inhibitory vs. noninhibitory properties at the mono-
clonal and polyclonal serum antibody level in TB.
Discussion
The role of humoral immune responses in TB is still highly contro-
versial (Achkar et al, 2015). We here demonstrate that the plas-
mablast antibody response to MTB infection in humans generates
functionally active antibodies. The expression of high-binding
somatically mutated and class-switched antibodies suggests that
these antibodies underwent multiple rounds of selection to reach
higher affinity and most likely developed with the help of T cells in
germinal center reactions. In low-incidence countries, the vast
majority of active TB cases are believed to be the consequence of
disease reactivation in individuals with latent TB infection, who
failed to contain MTB within solid granulomas (Small et al, 1994).











































































Figure 6. Fc receptor expression on human lung epithelial cells.
A Human lung epithelial A549 cells and primary bronchial epithelial cells (hAECB) lack FccR (CD16, CD64, and CD32) and FcaR (CD89) cell surface expression as analyzed
by flow cytometry. Human THP1 cells serve as a positive control.
B The neonatal FcR (FcRn) is expressed in both A549 cells and human THP1 cells as determined by Western blotting. Data are representative of at least two
independent experiments.
C Absolute bacterial counts (CFUs) in human THP1 macrophages 1 h after infection with MTB preincubated with the LAM-reactive IgA1 (left) or IgG1 (right) antibody
TB24PB037 or the respective isotype control antibody as indicated. Mean and SEM are indicated.
Data information: Data are representative of three independent experiments.
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Thus, it is likely that the plasmablast response studied here origi-
nated from reactivated memory B cells that were generated during
local immune responses to primary MTB infection. Indeed, prolifer-
ating and nonproliferating IgA+ plasma cells as well as small
numbers of IgG plasma cells could be detected adjacent to caseous
necrotic granulomas in the lung sections of TB patients with active
disease (Fig EV1). The clear bias toward IgA and the fact that
MTB-specific IgA and IgG memory B cells can be isolated from the
peripheral blood of healthy TB-exposed HCW—as demonstrated for
anti-HBHA memory B cells—suggests that the anti-MTB B-cell
response spreads from the lung to the periphery independently of
active TB disease.
Our data demonstrate that a substantial fraction of the plas-
mablast response is directed against cell membrane antigens includ-
ing ManLAM, a target of protective antibodies (Brown et al, 2003).
Thus, the targeted induction of high-affinity antibodies and memory
B cells against MTB surface antigens such as ManLAM or HBHA
could protect against primary infection prior to MTB entry into the
lung parenchyma and the establishment of stable infection, for
example, by inhibiting the interaction with the mannose receptor on
macrophages or through binding to proteoglycans on the surface of
epithelial cells, respectively (Teitelbaum et al, 1998; Pethe et al,
2001; Hamasur et al, 2004; Kang et al, 2005). Although we did not
detect differences in the specificity of antibodies cloned from dif-
ferent donors, it is likely that the target antigen specificity and the
affinity of memory B cell, plasmablast, and total serum antibodies
play a major role in determining the overall functionality of the
humoral immune response. However, antibody cross-reactivity does
not seem to influence the inhibitory activity of anti-MTB antibodies.
Airway responses are typically IgA biased, and passive immu-
nization with IgA can protect against early MTB infection of the lung
(Brandtzaeg et al, 1997; Rojas & Apodaca, 2002; Williams et al,
2004; Buccheri et al, 2007; Balu et al, 2011). However, IgG
responses develop particularly under inflammatory conditions and
anti-MTB IgG serum levels are higher in patients with active disease
compared with HCW (Demkow et al, 2007; Pukazhvanthen et al,
2014). Differences in antigen specificity and/or affinity or low anti-
MTB antibody titers may explain the lack of any inhibitory or
enhancing effect for individual monoclonal antibodies and serum
IgA or IgG preparations from individual donors, respectively. How
antibody isotype differences influence the course of natural MTB
infection in humans and whether isotype switching precedes the
development of active TB or reflects a consequence of disease
remain to be determined, but our data suggest that the expression of
IgG may promote MTB uptake by alveolar epithelial cells.
Experiments in mice have demonstrated a protective role for
antibodies in certain infection models. For example, intranasal
administration of MTB together with a mouse monoclonal anti-
HBHA IgG delayed bacterial dissemination to the spleen and liver,
without affecting the bacterial load in the lung (Pethe et al, 2001).
In contrast, intravenous infection and administration of a
LAM-specific murine IgG led to a reduction in the bacterial load in
the lung and was associated with the prolonged survival (Hamasur
et al, 2004). Collectively, these published data suggest that the
protective function of anti-MTB antibodies, at least in part, may
depend on the target antigen and host cell type, the local environ-
ment, and the route of administration (mucosa vs. periphery;
Falero-Diaz et al, 2000; Pethe et al, 2001; Chambers et al, 2004;
Hamasur et al, 2004; Williams et al, 2004; Roy et al, 2005;
Lopez et al, 2009). However, no systematic comparison of isotype-
associated functional differences has been made previously. Our
data suggest that antibody isotype differences in preexisting memory
B cells and plasma cells together with the differences in the antigen/
epitope specificity of the antibody response may play a major role in
modulating the course of the infection and the development and
progression of disease in humans. The targeted induction of IgA
memory B cells and serum antibodies may help to protect from
MTB infection or promote immunity upon primary exposure. Due to
the incomplete Fc receptor homology and the differences in expres-
sion patterns between mice and humans, mouse models may be
insufficient to assess the isotype-associated functional differences
for human antibodies in vivo even if chimeric antibody constructs
with murine Fc parts were generated (Bournazos et al, 2015). The
development of mice expressing human Fc receptors may be neces-
sary to overcome these limitations (van Egmond et al, 1999;


































































































Figure 7. IgA and IgG isotype-associated differences in the effect of TB serum antibodies on MTB infection of human lung epithelial cells.
A Absolute bacterial counts (CFUs) in human lung epithelial A549 cells 1 h after infection with MTB preincubated with purified serum IgA (left) or IgG (right) antibodies
from TB patients (TB) compared with HD as indicated. Mean and SEM are indicated. Data are representative of three independent experiments with three technical
replicates each.
B Direct comparison of purified serum IgA and IgG antibodies on epithelial cell invasion as measured in (A). P-value was determined using Wilcoxon–Mann–Whitney
test; ****P < 0.0001.
Data information: Data are representative of two independent experiments with three technical replicates each. Dotted lines indicate the medium control.
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understanding of the mechanisms underlying the development,
induction, and function of IgA vs. IgG responses in humans as well
as the identification of protective MTB target epitopes can form the
basis for the rational design of a vaccine, which not only prevents
TB disease, but also stable MTB infection.
Materials and Methods
Study participants
Patients included in this study were 19–57 years of age (mean
42  10 years). Active pulmonary TB was diagnosed by the pres-
ence of typical clinical symptoms in conjunction with a chest X-ray
compatible with TB as well as the diagnosis of MTB by sputum
smear microscopy and/or positive culture. After signed informed
consent was obtained, peripheral blood was drawn before or after
the start of therapy, as indicated.
Healthcare workers (HCW) who have been working with TB
patients for several years were recruited at the Charite´ Hospital,
Berlin.
Peripheral blood from healthy donors (HD) with no history of
MTB infection and no reported contact with TB patients served as
controls. Peripheral blood mononuclear cells and plasma were puri-
fied using Ficoll gradient density centrifugation.
Bacteria, bacterial fractions, antigens, and cell lines
All assays were performed using the MTB strain H37Rv. For the
assessment of monoclonal antibody binding to mycobacteria by
flow cytometry, the attenuated vaccine strain M. bovis Bacillus
Calmette–Gue´rin (BCG; Denmark background SSI) was used. Bacte-
ria were grown in Middlebrook 7H9 broth supplemented with
Middlebrook ADC, 0.05% Tween-80, and 0.5% glycerol, or on
Middlebrook 7H11 agar plates supplemented with Middlebrook
OADC and 0.05% Tween-80. Before the host cell infection, bacteria
were diluted to a multiplicity of infection (MOI) of 1 and passaged
five times through a tuberculin syringe to obtain the single-cell
suspensions. Unless indicated otherwise, all mycobacterial fractions
including the H37Rv cell membrane fraction (NR-14831), H37Rv
culture filtrate proteins (NR-14825), and all purified mycobacterial
antigens including the H37Rv LAM (NR-14848) were obtained from
BEI Resources, NIAID, NIH.
Native HBHA was expressed and purified from M. bovis BCG by
heparin-Sepharose chromatography followed by reverse-phase
HPLC as previously described (Menozzi et al, 1996; Masungi et al,
2002).
The human epithelial cell line A549 (ATCC; CCL-185) was
cultured in DMEM (GIBCO) containing 10% heat-inactivated FBS,
10 mM HEPES buffer solution, 1 mM sodium pyruvate, and 2 mM
L-glutamine. The human monocytic THP-1 cell line (ATCC; TIB-202)
was grown in RPMI 1640 (GIBCO), supplemented with 10% (v/v)
heat-inactivated fetal calf serum (FCS; GIBCO), 1% (v/v) penicillin–
streptomycin (GIBCO), 1% (v/v) sodium pyruvate (GIBCO), 1%
(v/v) L-glutamine (GIBCO), and 1% (v/v) HEPES buffer (GIBCO).
The THP-1 monocytic cell line was differentiated into macrophages
in RPMI medium containing 5 ng/ml phorbol 12-myristate
13-acetate (PMA, Sigma) for 72 h. Primary human airway epithelial
cells isolated from bronchial biopsies (hAECB) were purchased from
Epithelix Sa`rl and propagated using gamma-irradiated NIH/3T3 cells
as feeders (Suprynowicz et al, 2012). hAECB cells at 70–80% con-
fluence were separated from feeders by differential trypsinization
and passaged to new culture vessels with CnT-Prime Airway
medium (CELLnTEC) (A. Imai-Matsushima and T.F. Meyer, manu-
script in preparation).
Flow cytometry
Purified peripheral blood mononuclear cells were stained for
30 min at 4°C with the following panel of mouse anti-human
antibodies: CD19 PE-Cy7 (1:25 dilution), IgG V450 (1:20), CD27
FITC (1:25), CD38 PE (1:25), IgA biotin (1:100, all from BD Bios-
ciences) and CD21 APC (1:20; eBioscience). 7AAD (1:200; Life
Technologies) was used to exclude dead cells. Biotin-labeled anti-
bodies were detected with streptavidin-Qdot605 (1:100; Life Tech-
nologies). BD Bioscience LSRII and Aria I instruments were used
for flow cytometric analyses, and Aria II was used for single-cell
sorting.
Human lung A549 epithelial cells, human nAECB primary
epithelial cells, and human THP-1 monocytes were harvested
from culture dishes using either trypsin–EDTA or 3% EDTA and
stained with the following anti-human antibodies: CD89 PE (1:10;
Biolegend), CD32 PE (1:10; Biolegend), CD16 PE (1:10; BD Bios-
ciences), and CD64 PE (1:10; BD Biosciences). PE-labeled mouse
anti-human IgG1 j and IgG2 j antibodies (Biolegend) served as
isotype controls.
Single-cell sorting, antibody cloning, and expression
Recombinant monoclonal antibodies were generated as previously
described (Tiller et al, 2008). In brief, total mRNA was transcribed
using random hexamer primers. IGH and IGK or IGL chain tran-
scripts were amplified, sequenced, and cloned into heavy (IgG1,
IgA1, or IgA2; Lorin & Mouquet, 2015) or light chain (Igj or Igk)
expression vectors. Recombinant antibodies were produced in
human HEK 293T cells. Recombinant monoclonal IgG or IgA anti-
bodies were purified from culture supernatants using Protein G
Fast Flow Sepharose (GE Healthcare) and Protein M Agarose
(Invivogen), respectively. Antibodies were eluted from the column
by 0.1 M glycine pH 3 and the pH was neutralized with Tris buffer
(pH 8). IgG and IgA concentrations were determined by ELISA.
Individual batches of final antibody preparations were checked for
endotoxin levels with the LAL Chromogenic Endotoxin Quan-
tification Kit (Pierce) following the manufacturer’s instructions
before use in functional assays and were tested negative for LPS
contaminations.
For the functional assays, purified serum antibodies were
isolated from plasma using Protein G Fast Flow Sepharose (GE
Healthcare) or Protein M Agarose (Invivogen), respectively. Elution
and concentration measurements were done as described for mono-
clonal antibody preparations.
Sequence analysis
Sequence analyses of the IGH, IGK, and IGL chain transcripts were
performed using the IgBlast database to identify germline V(D)J
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genes with the highest homology. Somatic hypermutations were
determined as previously described (Tiller et al, 2008). The isotype
of memory B cells was determined by FACS analysis and the isotype
of plasmablast cells by sequence analysis. Sequence and FACS data
matched to over 95% when directly compared for memory B cells of
TB patient 7.
ELISA
Polyclonal serum or recombinant monoclonal antibody reactivity
was measured as follows. High-binding microtiter plates (Nunc)
were coated with 50 ll H37Rv lysate, cell membrane fraction,
culture filtrate proteins, or purified native HBHA at a final concen-
tration of 10 lg/ml overnight at 4°C. The plates were blocked with
4% BSA for 1.5 h at room temperature (RT), washed with 0.05%
PBS–Tween or PBS, and incubated with diluted plasma or mono-
clonal antibodies (mAbs) in 0.05% PBS–Tween–1% BSA (plasma)
for 2 h or PBS (mAbs) at RT followed by another washing step.
HRP-coupled goat anti-human IgG (H+L) antibody at a 1:1000 dilu-
tion (Jackson ImmunoResearch) and one-step ATBS substrate
(Roche) were used for detection. Area under the curve (AUC) values
were calculated with the GraphPad PRISM software. Antibodies
were considered MTB reactive when they recognized antigens in the
MTB lysate. Antibodies were considered cross-reactive when they
recognized at least two out of the four structurally different anti-
gens: MTB lysate, double-stranded DNA, insulin, and LPS. An inter-
nal negative control antibody (mGO53; Wardemann et al, 2003)
was included in all ELISAs.
Concentration ELISAs were performed as previously described
(Tiller et al, 2008). In brief, anti-human Fc-binding IgG (Dianova)
was coated overnight at a 1:500 dilution at RT. The plates were
blocked with PBS–0.05% Tween for 1 h at RT before incubation
with the purified recombinant antibodies for 1.5 h at RT. Human
IgG1k from the plasma of myeloma patients (Sigma) was used as
standard. Signals were detected as described above.
For LAM ELISAs, MTB Erdman ManLAM and M. smegmatis
PILAM were purified and quality control was performed as
described previously (Torrelles et al, 2008). Purified LAM (1 lg/
well in 0.05 M carbonate–bicarbonate buffer, pH 9.5) was adhered
to the wells of an ELISA medium binding plate overnight at 37°C;
control wells were left without LAM coating. The wells were washed
three times with PBS and blocked with 5% HSA–PBS overnight at
4°C. Blocked wells were washed and incubated with human
TB24PB037 antibody, human control antibody (mGO53; Warde-
mann et al, 2003), or the positive control murine CS-35 antibody in
0.5% HSA–PBS overnight at 4°C. The wells were washed and incu-
bated with HRP-conjugated secondary antibody (1:1,000 dilution;
Abcam) in 0.5% HSA–PBS for 2 h at RT. The wells were washed
and incubated with HRP substrate (Bio-Rad) at RT for 20 min. The
reaction was stopped with 0.2 N sulfuric acid, and the absorbance
was measured at 450 nm.
Infection assay
A549 epithelial cells were grown overnight at 2.5 × 105 cells/well
in 96-well plates. Prior infection, THP-1 monocytic cells (1 × 106
cells/well) were differentiated into macrophages as described
above. H37Rv bacteria were grown to OD 0.4–0.8, washed with
PBS, and passaged five times through a tuberculin syringe to
obtain single-cell suspensions. Recombinant monoclonal antibodies
at 10 lg/ml or diluted purified serum IgG/IgA were incubated with
1 × 108 bacteria for 1 h at 37°C. The cells were washed with FCS-
free medium and infected with H37Rv alone or with the antibody–
H37Rv mix at an MOI of 1 for 1 h at 37°C. Each condition was
tested in triplicate. Cells infected with MTB alone and infected
with MTB preincubated with the monoclonal isotype control anti-
body (mGO53; Wardemann et al, 2003) were used as internal
controls. Infected cells were vigorously washed four times with
PBS and lysed with 0.5% Triton X-100. Serial dilutions of cell
lysates were plated, and the bacterial counts (CFUs) were enumer-
ated at day 21.
Determination of FcRn expression by Western blot
A549 and THP1 cells were lysed for 5 min on ice with lysis buffer
containing 25 mM Tris–HCl pH 7.4, 150 mM NaCl, 1% NP-40,
1 mM EDTA, and 5% glycerol (Pierce). Cell debris was removed by
centrifugation, and the cell supernatant was analyzed for FcRn and
b-actin protein expression by Western blotting using the following
antibodies: anti-human FcRn (1:20 dilution; Novus; NBP1-89128),
anti-mouse b-actin (1:1,000; Cell Signaling Technology; 13E5), goat
anti-mouse IgG HRP conjugate (1:5,000 dilution; Jackson Immuno-
Research), and goat anti-rabbit HRP conjugate (1:5,000 dilution;
Jackson ImmunoResearch).
Immunohistochemistry and immunofluorescence staining
Lung sections from MTB patients were fixed with 4% paraformalde-
hyde (PFA) for 1 h and 1% PFA overnight and then embedded in
paraffin. Immunostainings were performed after heat-mediated anti-
gen retrieval, using DyLightTM594 affinity-purified goat anti-human
IgA (10 lg/ml; Jackson ImmunoResearch) and DyLightTM649 IgG
(10 lg/ml; Jackson ImmunoResearch). Intracellular stainings with
polyclonal rabbit anti-human Ki-67/MKI67 antibodies (1:100;
Novus) followed by AlexaFluor488-conjugated anti-IgG secondary
antibodies (1:100; Jackson ImmunoResearch) were performed after
permeabilization with 0.5% Triton X-100.
Statistics
Statistical significance was determined as described in
Appendix Table S5. D’Agostino–Pearson omnibus test was used to
determine the normal distribution. Unpaired t-test or Wilcoxon–
Mann–Whitney test was used as indicated. Statistical analyses were
performed with GraphPad Prism software. A value less than
P < 0.05 was considered statistically significant (*P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001).
Study approval
All investigations have been conducted according to the Declaration
of Helsinki principles. Ethical approval was obtained from Charite´
University Institutional Review Board (No. EA4/099/11). Written
informed consent was received from all participants prior to inclu-
sion in the study. Formalin-fixed, paraffin-embedded lung tissues
from three patients with pulmonary MDR-TB were obtained from
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the Republican Research and Practical Centre for Pulmonology and
Tuberculosis (RRPCPT). The use of human biopsies was based on
informed patient consent and approved by the ethics commission of
the RRPCPT.
Data availability
The data reported in this paper are tabulated in Appendix and are
archived at GenBank (accession number KX947385–KX949063).
Expanded View for this article is available online.
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